CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving... (isevon Willebrand factor in the bloodstr...)

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies

Date:4/3/2008

ise von Willebrand factor in the bloodstream(ii).

About Helixate(R) FS and Humate-P(R)

Helixate(R) FS is a recombinant version of the human factor VIII (FVIII) produced with the help of baby hamster kidney (BHK) cells. It is used to treat hemophilia A when there is a demonstrated deficiency of the above mentioned factor FVIII, a plasma clotting factor. Helixate(R) FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations or known sensitivity to mouse or hamster protein.

Helixate(R) FS should not be used to treat people with VWD since it does not contain the von Willebrand factor, the endogenous protein which is absent or defective in the VWD. For more information about von Willebrand disease, please visit http://www.allaboutbleeding.com.

Adverse events related to the use of Helixate (R) FS are generally minor. The most common events include injection-site reactions, dizziness and rash.

Humate-P(R) is a stable, purified, sterile, lyophilized concentrate of Antihemophilic Factor (Human) and von Willebrand Factor (vWF) (Human) complex used for the treatment of patients with classical hemophilia (hemophilia A) and VWD.

Humate-P(R) is usually tolerated without reaction. It should be administered with caution to patients with a known allergic reaction to constituents of the preparation. Cases of allergic reactions and rise in body temperature have been observed. Anaphylactic reactions can occur in rare instances. Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P(R) is made from human plasma and there is a theoretical risk that it may contain pathogens susceptible to cause diseases such as the hepatitis viruses, HIV and,
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. CSL Behring Expands Into Middle East Market with Haemate(R) P
2. Siemens Completes Acquisition of Dade Behring
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
5. Pharsight Signs Two New DMX(R) License Customers
6. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
7. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
8. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

Post Your Comments:

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving...(isevon Willebrand factor in the bloodstr...)